Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis.

ABSTRACT:

Background/aims

Fexuprazan is a novel potassium-competitive acid blocker that could be of benefit to patients with gastric mucosal injury. The aim of this study was to assess the 2-week efficacy and safety of fexuprazan in patients with acute or chronic gastritis.

Methods

In this study, 327 patients with acute or chronic gastritis who had one or more gastric erosions on endoscopy and subjective symptoms were randomized into three groups receiving fexuprazan 20 mg once a day (q.d.), fexuprazan 10 mg twice a day (b.i.d.), or placebo for 2 weeks. The posttreatment assessments were the primary endpoint (erosion improvement rate), secondary endpoints (cure rates of erosion and edema and improvement rates of redness, hemorrhage, and subjective symptoms), and drug-related adverse e

SUBMITTER: Kim GH 

PROVIDER: S-EPMC10651377 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature